PT Kimia Farma Tbk (KAEF) has established a good cooperative relationship with Sinopharm, especially in the provision of vaccines related to Covid-19 until now the national Covid-19 situation has been under control. In order to increase existing business potential, KAEF again signed a Memorandum of Understanding (MoU) with Sinopharm in Beijing.

This collaboration was strengthened through the signing of a Memorandum of Understanding regarding cooperation in the development of Medicinal Raw Materials (BBO), Traditional Chinese Medicine (TCM) and the TB Platform Project. The Memorandum of Understanding was signed by David Utama, Main Director of KAEF and Zhou Song, President of Sinopharm International, and witnessed by Main Director of Bio Farma Group Honesti Basyir and Chairman of Sinopharm Liu Jingzhen.

"This agreement is a continuation of the collaboration between Kimia Farma and Sinopharm which was well established during the handling of Covid-19. Kimia Farma supports national health resilience, one of which is by strengthening and accelerating Medicinal Raw Materials (BBO). Currently Kimia Farma has produced 14 BBO and we will continue to increase it," said David Utama, Main Director of KAEF.

David further said that this agreement is also a form of bilateral relations between the two countries to improve and encourage the transformation of the health industry.

“KAEF is committed to providing the best health products and services. We will follow up on this Memorandum of Understanding to support Government programs in the health sector and improve the health of the Indonesian people," added David